Skip to main content
construction release_alert
Scholars@Duke will be down for maintenance for approximately one hour starting Tuesday, 11/11 @1pm ET
cancel
Journal cover image

A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease.

Publication ,  Journal Article
Falloon, K; Cohen, B; Ananthakrishnan, AN; Barnes, EL; Bhattacharya, A; Colombel, J-F; Cross, RK; Driscoll, MS; Fernandez, AP; Ha, C; Horst, S ...
Published in: Aliment Pharmacol Ther
May 2022

BACKGROUND AND AIMS: Extra-intestinal manifestations (EIMs) are a common complication of inflammatory bowel diseases (IBD), affecting up to half of the patients. Despite their high prevalence, information on standardised definitions, diagnostic strategies, and treatment targets is limited. METHODS: As a starting point for a national EIM study network, an interdisciplinary expert panel of 12 gastroenterologists, 4 rheumatologists, 3 ophthalmologists, 6 dermatologists, and 4 patient representatives was assembled. Modified Delphi consensus methodology was used. Fifty-four candidate items were derived from the literature review and expert opinion focusing on five major EIMs (erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis) were rated in three voting rounds. RESULTS: For use in a clinical practice setting and as part of the creation of a prospective registry of patients with EIMs, the panel developed definitions for erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis; identified the appropriate and optimal subspecialists to diagnose and manage each; provided methods to monitor disease course; offered guidance regarding monitoring intervals; and defined resolution and recurrence. CONCLUSIONS: Consensus criteria for appropriate and optimal means of diagnosing and monitoring five EIMs have been developed as a starting point to inform clinical practice and future trial design. Key findings include straightforward diagnostic criteria, guidance regarding who can appropriately and optimally diagnose each, and monitoring options that include patient and physician-reported outcomes. These findings will be used in a national multicenter study network to optimise the management of EIMs.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Aliment Pharmacol Ther

DOI

EISSN

1365-2036

Publication Date

May 2022

Volume

55

Issue

9

Start / End Page

1179 / 1191

Location

England

Related Subject Headings

  • Uveitis
  • United States
  • Pyoderma Gangrenosum
  • Inflammatory Bowel Diseases
  • Humans
  • Gastroenterology & Hepatology
  • Follow-Up Studies
  • Erythema Nodosum
  • Consensus
  • Arthritis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Falloon, K., Cohen, B., Ananthakrishnan, A. N., Barnes, E. L., Bhattacharya, A., Colombel, J.-F., … Rieder, F. (2022). A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. Aliment Pharmacol Ther, 55(9), 1179–1191. https://doi.org/10.1111/apt.16853
Falloon, Katherine, Benjamin Cohen, Ashwin N. Ananthakrishnan, Edward L. Barnes, Abhik Bhattacharya, Jean-Frederic Colombel, Raymond K. Cross, et al. “A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease.Aliment Pharmacol Ther 55, no. 9 (May 2022): 1179–91. https://doi.org/10.1111/apt.16853.
Falloon K, Cohen B, Ananthakrishnan AN, Barnes EL, Bhattacharya A, Colombel J-F, et al. A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. Aliment Pharmacol Ther. 2022 May;55(9):1179–91.
Falloon, Katherine, et al. “A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease.Aliment Pharmacol Ther, vol. 55, no. 9, May 2022, pp. 1179–91. Pubmed, doi:10.1111/apt.16853.
Falloon K, Cohen B, Ananthakrishnan AN, Barnes EL, Bhattacharya A, Colombel J-F, Cross RK, Driscoll MS, Fernandez AP, Ha C, Herfarth H, Horst S, Hou J, Husni ME, Kroshinsky D, Kuhn KA, Lowder CY, Martin G, Parikh D, Sayed CJ, Schocket L, Siaton BC, Vedak P, Weisman MH, Rieder F. A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. Aliment Pharmacol Ther. 2022 May;55(9):1179–1191.
Journal cover image

Published In

Aliment Pharmacol Ther

DOI

EISSN

1365-2036

Publication Date

May 2022

Volume

55

Issue

9

Start / End Page

1179 / 1191

Location

England

Related Subject Headings

  • Uveitis
  • United States
  • Pyoderma Gangrenosum
  • Inflammatory Bowel Diseases
  • Humans
  • Gastroenterology & Hepatology
  • Follow-Up Studies
  • Erythema Nodosum
  • Consensus
  • Arthritis